Background: We conducted a phase I/II trial to evaluate the safety and immunogenicity of a novel vaccination with α-type-1-polarized dendritic cells (αDC1) loaded with synthetic peptides for glioma associated antigen (GAA) epitopes and administration of poly-ICLC in HLA-A2+ patients with recurrent malignant gliomas. GAAs for these peptides are EphA2, IL-13Rα2, YKL-40 and gp100. Methods: The study enrolled twenty-two recurrent malignant glioma patients with glioblastoma (GBM) (n = 13), anaplastic astrocytoma (n = 5), anaplastic oligodendroglioma (n = 3), or anaplastic oligoastrocytoma (n = 1). Half the patients had 2nd relapse or greater. Two recurrent GBM patients had prior bevacizumab. Peptide-loaded αDC1 were injected intra/perinodally every two weeks for 4 injections with the possibility of boosters. 20 µg/kg poly-ICLC was administered intramuscularly two times per week for 8 weeks. Immunogenicity was assessed by ELISPOT, tetramer, and IL-12 assays. Efficacy was determined by MRI according
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